Does This Lymph Node Look Bulky to You? What Should We Do About It? A Survey of Thoracic Surgeons.
설문조사
2/5 보강
TL;DR
Significant variation is documented in how surgeons define bulky lymphadenopathy and its influence on treatment decisions, highlighting the need for standardized definitions.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: non-small cell lung cancer
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
LN status appeared to be a substantial factor influencing which patients are surgical candidates. [CONCLUSIONS] This study documented significant variation in how surgeons define bulky lymphadenopathy and its influence on treatment decisions and highlighted the need for standardized definitions.
OpenAlex 토픽 ·
Lung Cancer Diagnosis and Treatment
Lung Cancer Treatments and Mutations
Head and Neck Cancer Studies
Significant variation is documented in how surgeons define bulky lymphadenopathy and its influence on treatment decisions, highlighting the need for standardized definitions.
- 표본수 (n) 161
APA
Ian C. Bostock, Adam H. Fox, et al. (2026). Does This Lymph Node Look Bulky to You? What Should We Do About It? A Survey of Thoracic Surgeons.. The Annals of thoracic surgery, 121(5), 1195-1201. https://doi.org/10.1016/j.athoracsur.2025.09.012
MLA
Ian C. Bostock, et al.. "Does This Lymph Node Look Bulky to You? What Should We Do About It? A Survey of Thoracic Surgeons.." The Annals of thoracic surgery, vol. 121, no. 5, 2026, pp. 1195-1201.
PMID
41067607 ↗
Abstract 한글 요약
[BACKGROUND] Clinical lung cancer staging plays an integral role in determining surgical candidacy for patients with non-small cell lung cancer. Bulky or multistation mediastinal lymph nodes (LNs) may influence surgical candidacy. However, these characteristics lack standardized definitions. The objective of this study was to describe surgeons' perspectives on how they use these terms in their practices.
[METHODS] A 24-item survey was developed and distributed to surgeons participating in The Society of Thoracic Surgeons email list. The survey aimed to determine how surgeons define bulky mediastinal or multistation lymphadenopathy and how these definitions affect their decision to operate. Comparisons of how respondents defined LN characteristics were made by demographic and practice characteristics using the χ and Fisher exact tests.
[RESULTS] The survey was sent to 1336 individuals, opened by 653 (48.9%), and completed by 165 (5.9%), for an overall 12.4% response rate. Almost all respondents were general thoracic surgeons (n = 161; 98.2%). Most respondents agreed on the definition of an enlarged LN as ≥1 cm (n = 149; 90.3%). More variation was observed in the definition of bulky LN: 39% (n = 64) used a threshold of ≥2 cm, 24% (n = 40) used ≥3 cm, and approximately 33% (n = 53) did not define bulky by size criteria alone. Most respondents considered 2 or more LN stations as multistation disease (n = 147; 89.1%). LN status appeared to be a substantial factor influencing which patients are surgical candidates.
[CONCLUSIONS] This study documented significant variation in how surgeons define bulky lymphadenopathy and its influence on treatment decisions and highlighted the need for standardized definitions.
[METHODS] A 24-item survey was developed and distributed to surgeons participating in The Society of Thoracic Surgeons email list. The survey aimed to determine how surgeons define bulky mediastinal or multistation lymphadenopathy and how these definitions affect their decision to operate. Comparisons of how respondents defined LN characteristics were made by demographic and practice characteristics using the χ and Fisher exact tests.
[RESULTS] The survey was sent to 1336 individuals, opened by 653 (48.9%), and completed by 165 (5.9%), for an overall 12.4% response rate. Almost all respondents were general thoracic surgeons (n = 161; 98.2%). Most respondents agreed on the definition of an enlarged LN as ≥1 cm (n = 149; 90.3%). More variation was observed in the definition of bulky LN: 39% (n = 64) used a threshold of ≥2 cm, 24% (n = 40) used ≥3 cm, and approximately 33% (n = 53) did not define bulky by size criteria alone. Most respondents considered 2 or more LN stations as multistation disease (n = 147; 89.1%). LN status appeared to be a substantial factor influencing which patients are surgical candidates.
[CONCLUSIONS] This study documented significant variation in how surgeons define bulky lymphadenopathy and its influence on treatment decisions and highlighted the need for standardized definitions.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.